Literature DB >> 27618791

Targeting metabolic peculiarities: a potentially novel therapeutic approach for KRAS-mutant lung cancer?

Omar Abdel-Rahman1.   

Abstract

Entities:  

Year:  2016        PMID： 27618791      PMCID： PMC4999704          DOI： 10.21037/jtd.2016.06.72

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  18 in total

1.  Executive Summary: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Frank C Detterbeck; Sandra Zelman Lewis; Rebecca Diekemper; Doreen Addrizzo-Harris; W Michael Alberts
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

2.  Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?

Authors:  Joshua Bauml; Rosemarie Mick; Yu Zhang; Christopher D Watt; Anil Vachani; Charu Aggarwal; Tracey Evans; Corey Langer
Journal:  Lung Cancer       Date:  2013-06-24       Impact factor: 5.705

Review 3.  Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.

Authors:  Omar Abdel-Rahman
Journal:  Ther Adv Respir Dis       Date:  2016-02-18       Impact factor: 4.031

4.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Authors:  Pasi A Jänne; Alice T Shaw; José Rodrigues Pereira; Gaëlle Jeannin; Johan Vansteenkiste; Carlos Barrios; Fabio Andre Franke; Lynda Grinsted; Victoria Zazulina; Paul Smith; Ian Smith; Lucio Crinò
Journal:  Lancet Oncol       Date:  2012-11-28       Impact factor: 41.316

Review 5.  KRAS mutations in non-small cell lung cancer.

Authors:  Gregory J Riely; Jenifer Marks; William Pao
Journal:  Proc Am Thorac Soc       Date:  2009-04-15

Review 6.  Targeting RAS signalling pathways in cancer therapy.

Authors:  Julian Downward
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

7.  COSMIC 2005.

Authors:  S Forbes; J Clements; E Dawson; S Bamford; T Webb; A Dogan; A Flanagan; J Teague; R Wooster; P A Futreal; M R Stratton
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

8.  Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.

Authors:  Marcin Nicoś; Paweł Krawczyk; Bożena Jarosz; Marek Sawicki; Justyna Szumiłło; Tomasz Trojanowski; Janusz Milanowski
Journal:  Clin Exp Med       Date:  2015-04-23       Impact factor: 3.984

9.  Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies.

Authors:  Michael J Thun; Lindsay M Hannan; Lucile L Adams-Campbell; Paolo Boffetta; Julie E Buring; Diane Feskanich; W Dana Flanders; Sun Ha Jee; Kota Katanoda; Laurence N Kolonel; I-Min Lee; Tomomi Marugame; Julie R Palmer; Elio Riboli; Tomotaka Sobue; Erika Avila-Tang; Lynne R Wilkens; Jon M Samet
Journal:  PLoS Med       Date:  2008-09-09       Impact factor: 11.069

10.  Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities.

Authors:  Emma M Kerr; Edoardo Gaude; Frances K Turrell; Christian Frezza; Carla P Martins
Journal:  Nature       Date:  2016-02-24       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.